Bilateral Renal Artery Stenosis and Entresto: Not an Absolute Contraindication, But Requires Extreme Caution
Bilateral renal artery stenosis is not listed as an absolute contraindication to Entresto (sacubitril/valsartan) in the FDA label, but it carries significant risk and requires close monitoring of renal function. The FDA label specifically warns that "ENTRESTO may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis" and mandates monitoring renal function in these patients 1.
Understanding the Risk Profile
The concern stems from the ARB component (valsartan) within Entresto, which affects the renin-angiotensin-aldosterone system (RAAS). Current hypertension guidelines explicitly state that ARBs carry "a risk of acute renal failure in patients with severe bilateral renal artery stenosis" 2. This same warning applies to ACE inhibitors 3, 4.
The key distinction is between "contraindication" and "high-risk situation requiring monitoring." The 2018 ACC/AHA guidelines list bilateral renal artery stenosis as a contraindication for enalaprilat (IV ACE inhibitor) in hypertensive emergencies 3, 5, and the 2005 ESC guidelines state ACE-inhibitor treatment is "contra-indicated in the presence of bilateral renal artery stenosis" 6. However, the Entresto FDA label takes a more nuanced approach, acknowledging the risk without declaring it an absolute contraindication.
Clinical Decision-Making Algorithm
When considering Entresto in bilateral renal artery stenosis:
Assess severity and hemodynamic significance of the stenosis
- Severe bilateral stenosis (>70-80% narrowing) = highest risk
- Hemodynamically significant stenosis = GFR dependent on efferent arteriolar tone
Evaluate revascularization options first
- Consider renal artery angioplasty/stenting before initiating Entresto
- Case reports demonstrate successful use of Entresto after bilateral renal artery revascularization 7
If Entresto is deemed necessary despite bilateral stenosis:
- Start at the lowest dose (24/26 mg twice daily)
- Monitor serum creatinine and eGFR within 1-2 weeks of initiation
- Check potassium levels concurrently
- Down-titrate or interrupt if creatinine increases >30% from baseline 1
Recognize warning signs for discontinuation:
- Progressive azotemia
- Oliguria
- Acute kidney injury
- Severe hyperkalemia (>5.5-6.0 mEq/L)
Evidence for Renal Safety in Other Contexts
Importantly, in patients without renal artery stenosis, Entresto demonstrates favorable renal outcomes. Studies show it slows eGFR decline compared to ACE inhibitors or ARBs alone in heart failure patients with chronic kidney disease 8, 9, 10. The PARADIGM-HF and PARAGON-HF trials showed reduced risk of renal events (50% reduction in GFR or end-stage kidney disease) with sacubitril/valsartan 8.
Critical Pitfalls to Avoid
- Do not assume bilateral renal artery stenosis is an absolute contraindication based solely on ARB warnings—the FDA label for Entresto requires monitoring but does not prohibit use
- Do not initiate Entresto without baseline renal function assessment and a plan for close follow-up
- Do not continue Entresto if creatinine rises significantly (>30-50% increase) or oliguria develops
- Do not overlook the option of revascularization, which may allow safer use of guideline-directed medical therapy 7
The Bottom Line
While bilateral renal artery stenosis creates a high-risk scenario for acute renal failure with Entresto due to its ARB component, it is not an FDA-listed absolute contraindication. The decision requires weighing the mortality benefit of Entresto in heart failure against the risk of worsening renal function. In practice, consider revascularization first when feasible, and if Entresto must be used, initiate at low doses with intensive renal function monitoring. 1, 7